# A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

> **NCT05735275** · PHASE1 · UNKNOWN · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 252 (estimated)

## Conditions studied

- Advanced Or Metastatic Solid Tumor Malignancies

## Interventions

- **DRUG:** SHR-A2102

## Key facts

- **NCT ID:** NCT05735275
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-03
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735275, "A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05735275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*